-
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)
Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma ...
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research(Post)Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell ...
Guide to Western Blot Sample Preparation(Post)Western blotting remains a pivotal technique in the molecular biosciences for the detection, quantification, and analysis of proteins. Its utility spans numerous fields, including immunology, de ...
Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying ...
Lacnotuzumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the me ...
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure ...
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many canc ...
Non-Small Cell Lung Carcinoma: Understanding, Diagnosing, and Treating NSCLC(Post)Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological c ...
Antibody Seroconversion Response in COVID-19(Post)Seroconversion Implications in SARS-CoV-2 Diagnostic Testing Key Points: COVID-19, the pandemi ...
Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols (Post)Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols What is COVID-19? COVID-19, the dise ...
CRISPR-Cas Screening for Cell Viability(Post)Key Points Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a method of gene editing that uses ...
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detec ...
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin ly ...
Belimumab: Unveiling Its Role in Lupus and Beyond(Post)Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand n ...
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechani ...
Granulocytes Guide(Post)Explore the diverse roles and functionalities of granulocytes - neutrophils, eosinophils, basophils, and mast cells - as they form a critical line of defense in the immune system, res ...
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat ...
Volagidemab: A Breakthrough in GLP-1 Receptor Agonists for Metabolic Disorders(Post)Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How ...
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Ti ...
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How d ...
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer the ...
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune sys ...
Harnessing CD40 for Potent Anti-Tumor Immune Responses(Post)CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) a ...
Exploring the Frontier of Immunotherapy: T Cell Expansion(Post)In the realm of immunotherapy, T cell expansion has emerged as a pivotal strategy, holding promise in the treatment of various diseases, particularly cancer. T cells are a critical component o ...
Hydroxychloroquine: Potential Treatment for COVID-19(Post)Hydroxychloroquine: Potential Treatment for COVID-19 What is Hydroxychloroquine? Hydroxychloroquine (HC ...
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.
Abituzumab: Understanding Its Role in Cancer and Fibrosis Research(Post)Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechan ...
Carlumab: Exploring Its Mechanism, Clinical Potential, and Research Biosimilars(Post)Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progres ...
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumo ...
Narnatumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system ...
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune ...
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and i ...
Targeting VISTA: Unleashing the Power of T Cells in Cancer Therapy(Post)V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME) ...
Immunometabolism – A therapeutic perspective(Post)What is Immunometabolism? Immunometabolism is an exponentially growing, multi-disciplinary field of research aiming at deciphering the dynamic cellular and mol ...
Interleukin-8 signalling(Post)IL-8 Overview Interleukin-8 (IL-8), also known as CXCL8, was discovered over 30 years ago as a small molecule that could promote chemotaxis and induce the production ...
In Vivo CAR-T Engineering: The Dawn of Off-the-Shelf Immunotherapy(Post)Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells ...
Unlocking the Next Wave of Cancer Treatment: The Promise and Progress of CAR-T Cell Therapy(Post)Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric A ...
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Do ...
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking C ...
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not ...
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses, ...
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.Wha ...
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treat ...
29 PhD Thesis Writing Tips(Post)Explore 29 essential tips for crafting a compelling and well-structured PhD thesis, blending effective writing practices with time management and academic rigor for a successful dissertation jour ...
NLRP3 Inflammasome & Cytokine Secretion(Post)Nod-like receptors Nod like receptors (NLRs) are a versatile family of relatively recently discovered intracellular receptors which have a b ...
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune des ...
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver o ...
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine t ...
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Doe ...
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab ...
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By ...
Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines ...
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mec ...
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What i ...
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), are a critical component of the immune system. They play a vital role in defending the body against viral infections, intracel ...
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer ...
Ulocuplumab: Targeting CXCR4 in Cancer Research and Beyond(Post)Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cel ...
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research(Post)Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, r ...
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)What You Need to Know About DenosumabWhat is Denosumab?Denosumab is a monoclonal antibody used primarily to treat osteoporosis and bone-related complications in cancer patients. It targ ...
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating ...
Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential(Post)Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and im ...
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including ...
CD27 Activation: Strengthening the Immune Army Against Cancer(Post)Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activ ...
PVR: Balancing Immune Activation and Suppression in Cancer(Post)PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a ...
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune eva ...
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primar ...
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-li ...
Plonmarlimab: Advancing Anti-GM-CSF Therapy in Inflammatory Diseases(Post)Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab ...
Compatibility and Performance Assessment of the GenieColor Mycoplasma Detection Kit Across Diverse Laboratory Conditions(Post)MORV0013 functioned effectively in both qPCR machines and water baths, with or without paraffin oil, maintaining consistent sensitivity and specificity. MORV0013 performed reliably betw ...
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors ...
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease(Post)Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from a ...
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does ...
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejecti ...
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe adver ...
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40 ...
Diabetic Retinopathy: premature cellular senescence and microvascular dysfunction(Post)By Pietro Maria Bertelli, PhD Candidate, Queens University Belfast Introduction Eye complications are very frequent in patients with diabetes, a ...
Barrett’s Oesophagus to Oesophageal Adenocarcinoma – Review(Post)Oesophageal Adenocarcinoma is on the rise globally affecting more than 450,000 people worldwide (Pennathur, Gibson et al. 2013). Once diagnosed overall 5-year survival ranges from 15 % to ...
Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing t ...
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycop ...
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.Wha ...
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved fo ...
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evad ...
4-1BB: Energizing Immune Cells to Overcome Tumor Resistance(Post)Immunotherapy has become a central pillar in the fight against cancer, with a focus on enhancing the body’s natural defenses. Among the molecules at the forefront of immunotherapeutic re ...
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research(Post)Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various diseas ...
کیت سنجش فعالیت آنزیم تبدیل آنژیوتانسین II (ACE2)(Post)کیت سنجش فعالیت آنزیم تبدیل آنژیوتانسین II (ACE2) (فلورومتریک) آنزیم مبدل آنژیوتانسین II ، (ACE2, EC 3.4.17.23) یک متالوپروتا ...
Plozalizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. B ...
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respon ...
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macroph ...
Trained Immunity: How Your Innate Immune System Learns and Remembers(Post)For decades, immunologists believed that only adaptive immunity—the sophisticated system of T cells and B cells—could form lasting memories of past infections. The innate immune system, our body's fi ...
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By blo ...
PD-1 & PD-L1 Inhibitors(Post)window.SHOGUN_IMAGE_ELEMENTS = window.SHOGUN_IMAGE_ELEMENTS || new Array(); window.SHOGUN_IMAGE_ELEMENTS.push({ hoverImage: '', uuid: 's-9d0e3f85-cf60-457e-b32a-268d931a22ba' }) PD- ...
Metabolism or pluripotency – which regulates which? A chicken or the egg story.(Post)By Sophie Arthur How many diseases and conditions do you think exist in this world? Thousands? Hundreds of thousands? Maybe even millions? Unfortunately, I don’t know the answer. But what ...
COVID-19에서의 항체 반응: SARS-COV-2 진단 테스트에서의 혈청 전환 영향(Post)주요 포인트: COVID-19,SARS-COV-2에의한 유행성 코로나 바이러스 질환은 예비 데이터에 따르면, 전형적인 혈청 전환 및 면역 글로불린 클래스 (이소형) 전환 시간 과정을 따르는 것으로 나타났다. 증상 발병 2 주 후 임상 중증도와 ...
Distributors(Page)At Assay Genie, we're proud to support scientists in acheiving their research goals around the globe! Working with the right distributors is an important part of achieving our mission. C ...
101 एलिसा समस्या-निवारण की सलाह/टिप्स(Page){ "@context" : "http://schema.org", "@type" : "Article", "name" : "101 एलिसा समस्या-निवारण की सलाह/टिप", "author" : { "@type" : "Person", "name" : "Seán Mac Fhea ...
एलिसा प्लेट धोने की युक्तियाँ(Page){ "@context" : "http://schema.org", "@type" : "Article", "name" : "एलिसा प्लेट धोने की युक्तिय", "author" : { "@type" : "Person", "name" : "Eimear Nolan" }, ...
인터루킨 8 시그널링(Page){ "@context" : "http://schema.org", "@type" : "Article", "name" : "인터루킨 8 시그널링", "author" : { "@type" : "Person", "name" : "Eimear Nolan" }, "datePublished ...
IL-6 개요(Page){ "@context" : "http://schema.org", "@type" : "Article", "name" : "IL-6 개요", "author" : { "@type" : "Person", "name" : "Eimear Nolan" }, "datePublished" : ...
細胞溶解用超音波処理プロトコル(Page){ "@context" : "http://schema.org", "@type" : "Article", "name" : "細胞溶解用超音波処理プロトコル", "author" : { "@type" : "Person", "name" : "Eimear Nolan" }, "datePublis ...
세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜 (Page){ "@context" : "http://schema.org", "@type" : "Article", "name" : "세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜", "author" : { "@type" : "Person", "name" : "Eimear Nolan" }, ...